HEALTH CARE · KOSDAQ · 067630

HLB Life Science

HLB생명과학Small-capPharmaceuticals

What the company does

Company summary coming soon.

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$33.2M

▼ −55.2% YoY

Operating profit · FY2025

−US$16M

Loss narrowed

Net income · FY2025

−US$72.4M

Turned to loss

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025	US$; ₩ in tooltip
Revenue	US$71M(₩98B)	US$74.1M(₩102.2B)	US$33.2M(₩45.8B)
Operating profit	−US$17.8M(−₩24.5B)	−US$18M(−₩24.8B)	−US$16M(−₩22B)
Net income	−US$4.3M(−₩5.9B)	US$4.5M(₩6.2B)	−US$72.4M(−₩99.9B)

Revenue

FY2023US$71M
FY2024US$74.1M
FY2025US$33.2M

Operating profit

FY2023−US$17.8M
FY2024−US$18M
FY2025−US$16M

Net income

FY2023−US$4.3M
FY2024US$4.5M
FY2025−US$72.4M

Key ratios (FY2025)

ROE

-33.6%

Debt/Eq

60.6%

Op. margin

-48.1%

Net margin

-218.4%

Rev. YoY

▼ −55.2%

Filings

All disclosures · English when translated

전환사채(해외전환사채포함)발행후만기전사채취득 (제13회차)
Capital raise · Aug 31

Price charts coming soon

Interactive price history isn't here yet. Would you use it?